Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Jan 16, 2017; 9(1): 34-40
Published online Jan 16, 2017. doi: 10.4253/wjge.v9.i1.34
Published online Jan 16, 2017. doi: 10.4253/wjge.v9.i1.34
Table 1 Demographics and clinical characteristics of the inflammatory bowel disease type unclassified patients
No. of patients, n (%) | 36 (100) |
Gender | |
Female | 21 (58.3) |
Male | 15 (41.7) |
Age (yr) (mean ± SD) at diagnosis | 33.2 ± 13.1 (15-64) |
Age (yr) (mean ± SD) at SBCE | 35.9 ± 13.3 (18-64) |
Device (no. patients), n (%) | |
PillCam® SB1 | 13 (36.1) |
PillCam® SB2 | 16 (44.4) |
PillCam® SB3 | 1 (2.8) |
Mirocam® | 5 (13.9) |
Endocapsule® | 1 (2.8) |
Gastric transit time (min) | 38.6 ± 44.7 (2–257) |
Small bowel transit time (min) | 290.4 ± 101.5 (52-480) |
Incomplete SBCE | 1 (2.8) |
Capsule retention | 0 |
Follow-up (mo) before SBCE | 30.2 ± 29.9 (1-108) |
Follow-up (mo) after SBCE | 51.9 ± 40.5 (12-156) |
Table 2 Clinical characteristics and outcome of the patients with positive small bowel capsule
Case | Sex | Age | SBCE Findings | LS | Treatment pre-SBCE | Treatment post-SBCE | Diagnostic at follow-up |
1 | F | 38 | Multiple jejuno-ileal ulcerations | 1404 | 5ASA | 5 ASA + AZT | CD |
2 | F | 18 | Ulcer (n = 1) and edema of 3° tertile | 143 | AZT | Anti-TNF | CD |
3 | M | 23 | Ulcer (n = 1) and edema of 3° tertile | 143 | 5ASA | 5ASA | CD |
4 | F | 20 | Ulcerations (n = 2) and edema of 3° tertile | 233 | 5ASA | 5ASA | CD |
5 | F | 33 | Ulcer (n = 3) of 2° tertile | 225 | 5ASA | 5ASA | CD |
6 | F | 19 | Multiple ulcerations and edema of 3° tertile | 908 | 5ASA | AZT | CD |
7 | M | 60 | Focal edema of 1° tertile | 8 | No treatment | 5ASA | UC |
8 | M | 22 | Multiple jejuno-ileal ulcerations | 2080 | 5ASA | 5ASA + AZT | CD |
9 | F | 32 | Multiple ulcerations and edema of 3° tertile | 908 | 5ASA | AZT | CD |
10 | F | 27 | Focal edema of 3° tertile | 8 | Prednisolone | anti-TNF | UC |
11 | F | 47 | Focal edema of 2° tertile | 8 | 5ASA | 5ASA | UC |
12 | F | 31 | Ulceration and edema of 1° (n = 5) and 2° tertile (n = 6) | 879 | 5ASA+Prednisolone | AZT | CD |
13 | M | 44 | Focal edema of 3º tertile | 8 | 5ASA | 5ASA | UC |
Table 3 Clinical characteristics and outcome of the patients with negative small bowel capsule
Case | Sex | Age | Treatment pre-SBCE | Treatment post-SBCE | Diagnostic at follow-up |
1 | M | 45 | 5ASA | 5ASA | IBDU |
2 | F | 15 | Prednisolone, 5ASA | 5ASA | UC |
3 | F | 27 | AZT, 5ASA | AZT | UC |
4 | F | 26 | 5ASA | 5ASA | UC |
5 | M | 31 | 5ASA | 5ASA | IBDU |
6 | F | 34 | 5ASA | 5ASA | IBDU |
7 | M | 21 | 5ASA | 5ASA | IBDU |
8 | F | 22 | 5ASA | 5ASA, AZT | IBDU |
9 | F | 56 | 5ASA | 5ASA | UC |
10 | F | 27 | AZT, anti-TNF | AZT, anti-TNF | UC |
11 | F | 30 | 5ASA | 5ASA | UC |
12 | M | 24 | 5ASA | 5ASA | CD |
13 | M | 49 | 5ASA | 5ASA | UC |
14 | M | 43 | 5ASA | 5ASA | UC |
15 | F | 30 | 5ASA + AZT | Anti-TNF | IBDU |
16 | M | 24 | 5ASA | 5ASA | UC |
17 | F | 20 | 5ASA | 5ASA | UC |
18 | M | 55 | 5ASA | 5ASA | IBDU |
19 | F | 31 | 5ASA | 5ASA, AZT, Anti-TNF | UC |
20 | F | 48 | 5ASA | 5ASA, AZT | IBDU |
21 | M | 64 | 5ASA | 5ASA | UC |
22 | M | 44 | No treatment | 5ASA | IBDU |
23 | M | 53 | 5ASA | 5ASA | IBDU |
- Citation: Monteiro S, Dias de Castro F, Boal Carvalho P, Rosa B, Moreira MJ, Pinho R, Saraiva MM, Cotter J. Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. World J Gastrointest Endosc 2017; 9(1): 34-40
- URL: https://www.wjgnet.com/1948-5190/full/v9/i1/34.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i1.34